Načítá se...
Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice
Alcohol relapse is a treatment goal for alcohol dependence and the target for medications’ development. Clinically utilized nalfurafine (NFF) is a potent and selective kappa-opioid receptor (KOP-r) agonist, with fewer side effects (e.g., sedation or anhedonia) than classic KOP-r full agonists. We ha...
Uloženo v:
| Vydáno v: | Brain Res |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6779526/ https://ncbi.nlm.nih.gov/pubmed/31469985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.brainres.2019.146410 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|